<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50120">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01706029</url>
  </required_header>
  <id_info>
    <org_study_id>I11013/</org_study_id>
    <nct_id>NCT01706029</nct_id>
  </id_info>
  <brief_title>Pain Evaluation in Rheumatoid Arthritis</brief_title>
  <acronym>Douleur-PR</acronym>
  <official_title>Multidimensional Evaluation of Pain in Rheumatoid Arthritis (Douleur PR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid Arthritis (RA) is an inflammatory chronic rheumatism where the pain remains the
      priority domain of improvement for the patients instead a good control of the inflammatory
      disease by treatments, even biotherapeutics .

      Some studies show that less than 50 % of the patients is satisfied by the care of the pain,
      whereas the criteria of evaluation of the RA improve under treatment. The chronic pain, is a
      complex and multifactorial subjective phenomenon requiring a multidimensional evaluation,
      while the current criteria of follow-up of the RA (DAS28, ACR criteria) investigate the pain
      in a single dimension that is the pain intensity.

      So, the investigators do not arrange explanation for this observed dichotomy between the
      improvement of the clinical and biological inflammatory criteria of the RA and on the other
      hand the persistence of pain.

      On the other hand, the interleukin (IL)-6, IL-17 and IL-33 are cytokines occurring in the
      physiopathology of RA and probably in the pain processing according to recent data of the
      literature.

      The aim of this study is:

        -  to assess the multidimensional origin of the pain in  RA patients by means of
           questionnaires

        -  to look for a possible correlation between the serum level of  cytokines and pain.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Evaluation of the pain</measure>
    <time_frame>At day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Multidimensional evaluation of the pain using standard questionnaires: HAS, Beck and Speilberger , Erosion Narrow Score and Fibromyalgia diagnostic criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients pain care</measure>
    <time_frame>At day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimate the satisfaction of the patients towards the coverage (care) of their pain by means of  VAS and verbal scale of satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation</measure>
    <time_frame>At day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimate the correlation between the activity of the RA and the multidimensional evaluation of pain using DAS28 questionnaire</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sampling of blood for dosage of IL-6, IL-17 and IL-33 serum level
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are selected from those coming to the Department of Rheumatology of each
        partcipating center.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with RA treated with DMARDs and/or biotherapy,

          -  Capable of providing written consent

        Exclusion Criteria:

          -  Patients affected by a painful disease other one than RA,

          -  Fibromyalgia,

          -  A malignancy disease,

          -  An hemopathy,

          -  Psychiatric disorders or dementia and

          -  Acute infectious diseases and

          -  Receive or had received anti-IL6 therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascale Vergne-Salle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Limoges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascale Vergne-Salle, MD</last_name>
    <phone>0555058831</phone>
    <email>pascale.vergne-salle@chu-limoges.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Bordeaux- Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Richez, MD</last_name>
      <phone>0556795556</phone>
      <email>Christophe.richez@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe Richez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MS Soubrier, MD</last_name>
      <phone>04 73 75 14 88</phone>
      <email>msoubrier@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>MS Soubrier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital R. Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RM Flipo, MD</last_name>
      <phone>03 20 44 60 62</phone>
      <email>rmflipo@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>RM Flipo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale Vergne-Salle, MD</last_name>
      <phone>05 55 05 64 69</phone>
      <email>pascale.vergne-salle@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Pascale Vergne-Salle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel-Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serge Perrot, MD</last_name>
      <phone>01 42 34 84 49</phone>
      <email>serge.perrot@htd.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Serge Perrot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bois-Guillaume</name>
      <address>
        <city>Rouen</city>
        <zip>76230</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Vittecoq, MD</last_name>
      <phone>02 32 88 90 19</phone>
      <email>olivier.vittecoq@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier vittecoq, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Sibilia, MD</last_name>
      <phone>03 88 12 79 55</phone>
      <email>jean.sibilia@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Sibilia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 4, 2013</lastchanged_date>
  <firstreceived_date>October 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
